http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2600160-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0512499364e5d3049d8b7ca823ba646c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 |
| filingDate | 2015-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b7f0b431c715139bebe0cc63d30ba15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15035c029b458dc0992e87f247b15ab0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f98471f58dc4fe6b685edfadf0d1bfda |
| publicationDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2600160-C1 |
| titleOfInvention | Method of treating multiple sclerosis and other systemic autoimmune diseases |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to neurology, and can be used for treating multiple sclerosis. For this purpose, hemopoietic stem cells are prepared at the first stage using granulocyte colony-stimulating factor in dose of 10 mcg/kg for 4-5 days and freezed. It is followed by high-dose immune suppressive therapy with the help of Cyclophosphan 200 mg/kg and Rituximab 500 mg/m 2 / Carmustine 300 mg/m 2 , Cyclophosphan 120 mg/kg and Rituximab 500 mg/m 2 . That is followed by transplantation of hemopoietic stem cells, and for groups of patients with high risk of relapse supporting therapy with Mitoxantrone 12 mg/m 2 or Rituximab 375 mg/m 2 is additionally carried out quarterly during 1 year after THSC. Wherein, in parallel with high-dose immune suppressive therapy hydration and supporting therapy are performed by use of glucocorticosteroids, stimulation of hematopoiesis with colony-stimulating factors, nutritional and hemo-component therapy. n EFFECT: using this method is effective in treating patients with various forms of multiple sclerosis, thus allowing to achieve clinical improvement and stable prolonged remission. n 1 cl, 3 dwg, 2 tbl |
| priorityDate | 2015-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.